Literature DB >> 28816144

Comparison of Treatment Outcome Between Invasive Lobular and Ductal Carcinomas in Patients Receiving Partial Breast Irradiation With Intraoperative Electrons.

Maria Cristina Leonardi1, Patrick Maisonneuve2, Mauro Giuseppe Mastropasqua3, Federica Cattani4, Giuseppe Fanetti5, Anna Morra1, Roberta Lazzari1, Federica Bazzani5, Mariangela Caputo5, Nicole Rotmensz2, Marianna Alessandra Gerardi1, Rosalinda Ricotti1, Viviana Enrica Galimberti6, Paolo Veronesi7, Samantha Dicuonzo8, Giuseppe Viale9, Barbara Alicja Jereczek-Fossa5, Roberto Orecchia10.   

Abstract

PURPOSE: To investigate the local outcome of patients after accelerated partial breast irradiation with intraoperative electrons (IORT) for invasive lobular carcinoma (ILC) compared with invasive ductal carcinoma (IDC). METHODS AND MATERIALS: From 1999 to 2007, 2173 patients were treated with breast-conserving surgery and IORT (21 Gy/1 fraction) as the sole local treatment: 252 patients with ILC (11.6%) were compared with 1921 patients with IDC in terms of local control.
RESULTS: Compared with the IDC subgroup, patients with ILC had a low-risk profile and were more hormone responsive. The 5- and 10-year in-breast tumor reappearance (IBTR) rates were 5.5% and 14.4%, respectively, for the IDC group and 7.5% and 21.8%, respectively, for the ILC group (log-rank P=.03). The excess risk of IBTR associated with ILC was particularly high for small tumors (≤1 cm: hazard ratio [HR], 2.24; 95% confidence interval [CI], 1.03-4.85), elderly patients (60-69 years: HR, 2.27; 95% CI, 1.11-4.63; ≥70 years: HR, 3.28; 95% CI, 1.08-10.0), low-grade tumors (grade 1: HR, 3.50; 95% CI, 1.05-11.7), and luminal A molecular subtype (HR, 3.18; 95% CI, 1.49-6.77). Among the ILC histologic variants, no difference between classic and nonclassic subgroups was observed, although the signet ring cell and solid variants had the worst local control.
CONCLUSIONS: Despite a favorable tumor profile, accelerated partial breast irradiation with IORT led to a higher incidence of IBTRs in patients with ILC compared with those with IDC. Our institutional experience emphasized the importance of the size of the irradiation field, pointing to the use of larger collimators, even when dealing with small tumors, to improve local control.
Copyright © 2017 Elsevier Inc. All rights reserved.

Entities:  

Mesh:

Year:  2017        PMID: 28816144     DOI: 10.1016/j.ijrobp.2017.04.033

Source DB:  PubMed          Journal:  Int J Radiat Oncol Biol Phys        ISSN: 0360-3016            Impact factor:   7.038


  5 in total

1.  Intraoperative radiotherapy (IORT) versus whole-breast external beam radiotherapy (EBRT) in early stage breast cancer: results from SEER database.

Authors:  Juan Lei; Yi Wang; Zhuofei Bi; Shengneng Xue; Bing Ou; Kan Liu
Journal:  Jpn J Radiol       Date:  2019-11-05       Impact factor: 2.374

2.  [Intraoperative partial breast irradiation with electrons (ELIOT) compared to conventionally fractionated whole-breast irradiation of early-stage invasive breast cancer after breast-conserving surgery: long-term data from a prospective randomised trial].

Authors:  Gerd Fastner; Roland Reitsamer; Christoph Gaisberger; Markus Stana; Felix Sedlmayer
Journal:  Strahlenther Onkol       Date:  2021-10-01       Impact factor: 3.621

3.  Comparison of Local Recurrence Among Early Breast Cancer Patients Treated With Electron Intraoperative Radiotherapy vs Hypofractionated Photon Radiotherapy an Observational Study.

Authors:  Marina Guenzi; Elisabetta Bonzano; Renzo Corvò; Francesca Merolla; Alice Pastorino; Francesca Cavagnetto; Stefania Garelli; Carlo Alberto Cutolo; Daniele Friedman; Liliana Belgioia
Journal:  Front Oncol       Date:  2018-06-05       Impact factor: 6.244

4.  Efficacy analysis of intraoperative radiotherapy in patients with early-stage breast cancer.

Authors:  Lin Wang; Minmin Zhu; Yuelong Cui; Xudong Zhang; Guowen Li
Journal:  Cancer Cell Int       Date:  2020-09-11       Impact factor: 5.722

Review 5.  Altered fractionation in radiation therapy for breast cancer in the elderly: are we moving forward?

Authors:  Valentina Pinzi; Laura Fariselli; Barbara Alicja Jereczek-Fossa
Journal:  Transl Cancer Res       Date:  2020-01       Impact factor: 1.241

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.